Beryl Drugs ‘s Q2 Results: Profit Drops by 96.3% YoY

The comprehensive analytics outlining the performance and outlook of Beryl Drugs Ltd.‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Beryl Drugs Ltd.’s financial performance for the Q2(Sep 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -30.05 %. However, it did see a marginal slip of -10.16 % from the previous quarter. Expenses decreased slightly by -4.15 % quarter-on-quarter, aligning with the annual decline of -31.07 %. Operating profit, while down -19.7 % compared to last year, faced a quarter-on-quarter dip of -44.21 %, signaling a short-term contraction in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 1.22 %, but a shrinkage of -5.76 % sequentially. Other income fell by -18.42 % compared to the last quarter, despite an annual decline of -47.46 %. Interest expenses dropped significantly by -42.86 % from the previous quarter, yet the year-over-year increase remains at a moderate 20 %. Depreciation costs climbed by 21.43 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 13.33 %. Profit before tax declined annually by -68.75 % but saw a reduction from the preceding quarter by -80 %.
Tax expenses as a percentage of profits increased slightly by 77.57 % compared to last year, with a more notable quarter-on-quarter increase of 67.71 %. Net profit fell by -96.3 % year-on-year but witnessed a -97.3 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -98.15 % but a quarterly fall of -98.63 %. In summary, Beryl Drugs Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Beryl Drugs Ltd.’s 2024-25(Q2) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -30.05 % year-on-year, although there was a slight dip of -10.16 % from the previous quarter. Expenses decreased by -31.07 % compared to the previous year, with a decrease of -4.15 % quarter-on-quarter. Operating Profit dropped by -19.7 % annually, and saw a -44.21 % decrease from the last quarter.
Net Profit showed yearly decrease of -96.3 %, and experienced a -97.3 % decrease from the previous quarter. Earnings Per Share (EPS) fell by -98.15 % annually, however dipped by -98.63 % compared to the last quarter. In essence, while Beryl Drugs Ltd. faces strong annual decline indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.